Name: SXTC Income Statement - China Sxt Pharmaceuticals Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

SXTC - China Sxt Pharmaceuticals, Inc.

USD | NASDAQ | Healthcare

SXTC Income Statement - China Sxt Pharmaceuticals Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017
Revenues
Revenues	1.1	1.7	1.9	2.0	2.6	4.8	5.2	7.0	7.0	4.9
Cost of Revenue	0.9	1.4	1.4	1.5	1.4	1.9	2.5	2.4	3.6	2.6
Gross Profit	0.2	0.4	0.6	0.4	1.3	2.8	2.7	4.6	3.4	2.3
Operating Expenses
Research & Development	-	-	0.2	0.2	0.4	-	-	-	-	-
Selling General & Administrative	-	-	-
Operating Income
Operating Income	(7.1)	(2.7)	(2.5)	(5.6)	(5.2)	(2.2)	(1.3)	1.8	1.6	1.6
Non-Operating
Interest Income	-	-	-	-	-	-	-	-	-	-
Interest Expense	0.1	0.6	0.5	0.5
Tax & Net
Income Tax Expense	-	-	-	-	0.3	(0.2)	(0.1)	0.3	0.4	0.4
Net Income From Continuing Ops	(6.2)	(3.3)	(3.1)
Per Share
EPS Basic	(9.13)	(348.17)	(4,285.66)	(177.84)	(137.92)	(3.82)	33.28	0.08	0.06	0.06
EPS Diluted	(9.13)	(348.17)	(4,285.66)	(177.84)
Supplementary Data
EBITDA	(7.0)	(2.6)	(2.3)	(5.4)	(4.9)	(1.9)	(1.0)	2.0	1.8	1.7
EBIT	(7.1)	(2.7)	(2.5)	(5.6)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)